Bioventus Inc.

Análisis de la acción Bioventus Inc. (BVS)

$13.300

-0.491 (-3.69%)Al cierre

Loading chart…
Máximo
14.000
Apertura
13.830
Precio medio ponderado por volumen
13.51
Volumen
333.00K
Capitalización
365.09M
Mínimo
13.220
Importe
4.50M
EV/EBITDA, TTM
9.48

Bioventus Inc. is a medical device company. The Company’s portfolio of products is grouped into three areas. Its Pain Treatments include the Knee Osteoarthritis (KOA) area, and Peripheral Nerve Stimulation (PNS) area. Its Surgical Solutions include Ultrasonics, which offers precision bone resection for patients with degenerative spine conditions and spinal deformities, and Bone Graft Substitutes (BGS), which includes a range of products that facilitate optimal bone fusion following a surgical procedure. Its Restorative Therapies comprise Fracture Care that provide low-intensity pulse ultrasound to help patients who suffer from bone fractures that do not heal through traditional methods. It offers a diverse portfolio of products to support physicians in relieving pain and addressing musculoskeletal challenges across indications and clinical areas, including knee, hand and upper extremities, foot and ankle, podiatry, trauma, general surgery, spine and neurosurgery.

www.bioventus.com

Análisis de IA of Bioventus Inc. (BVS)

Comprar

Bioventus Inc is a good buy right now, given its current price of $13.30 and a forward P/E of 14.79, which suggests the stock is reasonably valued compared to its earnings potential. Additionally, the company has shown a significant year-to-date change of +84.47%, indicating strong momentum. The main risk is the recent strategic review initiated by the Board, which could lead to uncertainty regarding the company's future direction.

Métricas de valoración

El PER previsto actual de Bioventus Inc. (BVS) es 14.79, frente a su media de 5 años de 21.52.

PER previsto

Valor razonable
Media 5A P/E
21.52
P/E actual
14.79
Sobrevalorada
53.11
Infravalorada
-10.07

EV/EBITDA previsto

Valor razonable
Media 5A EV/EBITDA
8.82
EV/EBITDA actual
9.48
Sobrevalorada
10.92
Infravalorada
6.72

Precio/ventas previsto

Sobrevalorado
Media 5A P/S
0.87
P/S actual
1.46
Sobrevalorada
1.28
Infravalorada
0.46

Escenarios de precio de Alphio AI para BVS

Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

A

Alcista

Alcista · 25%BVS

$7.26

Precio del escenario

B

Base

Base · 50%BVS

$5.98

Precio del escenario

B

Bajista

Bajista · 25%BVS

$5.88

Precio del escenario

Ballenas con BVS en cartera

P

Pinnacle Investment Management Group Limited

+ Con en carteraBVS

-9.76%

Rentabilidad a 3 meses

Cronología de eventos

2026-08-05 (ET)

08:30:00

Bioventus Initiates Review of Strategic Alternatives

2026-06-30 (ET)

14:00:00

AWS Invests $1 Billion to Establish Forward Deployed Engineering Organization

2026-05-06 (ET)

08:10:00

Bioventus Raises FY26 Revenue Guidance to $600M

08:10:00

Bioventus Q1 Revenue $132.09M, Exceeds Expectations

2026-03-05 (ET)

07:20:00

Sees FY26 Revenue of $600M-$610M

Noticias

Preguntas frecuentes sobre BVS, respondidas por Alphio AI

Bioventus Inc. is a medical device company. The Company’s portfolio of products is grouped into three areas. Its Pain Treatments include the Knee Osteoarthritis (KOA) area, and Peripheral Nerve Stimulation (PNS) area. Its Surgical Solutions include Ultrasonics, which offers precision bone resection for patients with degenerative spine conditions and spinal deformities, and Bone Graft Substitutes (BGS), which includes a range of products that facilitate optimal bone fusion following a surgical procedure. Its Restorative Therapies comprise Fracture Care that provide low-intensity pulse ultrasound to help patients who suffer from bone fractures that do not heal through traditional methods. It offers a diverse portfolio of products to support physicians in relieving pain and addressing musculoskeletal challenges across indications and clinical areas, including knee, hand and upper extremities, foot and ankle, podiatry, trauma, general surgery, spine and neurosurgery. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Bioventus Inc is a good buy right now, given its current price of $13.30 and a forward P/E of 14.79, which suggests the stock is reasonably valued compared to its earnings potential. Additionally, the company has shown a significant year-to-date change of +84.47%, indicating strong momentum. The main risk is the recent strategic review initiated by the Board, which could lead to uncertainty regarding the company's future direction.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar